[Malignancy prediction in endocrine pancreas neoplasias].
Fernández-del Castillo
Carlos
C
Escuela de Medicina de Harvard, Massachusetts General Hospital, Boston 02114, USA.
D014408:Biomarkers, Tumor / Q000032:analysis; D002455:Cell Division; D002864:Chromogranins / Q000032:analysis; D006801:Humans; D007633:Keratins / Q000032:analysis; D019394:Ki-67 Antigen / Q000032:analysis; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis; D018358:Neuroendocrine Tumors / Q000737:chemistry / Q000145:classification / Q000000981:diagnostic imaging / Q000473:pathology* / Q000556:secondary / Q000601:surgery; D010146:Pain / Q000209:etiology; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000145:classification / Q000000981:diagnostic imaging / Q000473:pathology* / Q000601:surgery; D010751:Phosphopyruvate Hydratase / Q000032:analysis; D011379:Prognosis; D016708:Synaptophysin / Q000032:analysis; D014057:Tomography, X-Ray Computed
D014408:Biomarkers, Tumor; D002864:Chromogranins; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D016708:Synaptophysin; D007633:Keratins; D010751:Phosphopyruvate Hydratase